EC Number   |
Application |
Reference  |
|---|
   3.4.21.B42 | medicine |
KLK11 mRNA may serve as a marker to discriminate between benign prostatic hyperplasia and prostate cancer |
667879 |
| 3.4.21.B42 | medicine |
K11 is a serum marker for the diagnosis of ovarian carcinoma |
679272 |
| 3.4.21.B42 | medicine |
overexpression of human kallikrein 11 is associated with poor prognosis in patients with low rectal carcinoma |
693983 |
| 3.4.21.B42 | medicine |
the down-regulation of KLK11 gene in advanced and more aggressive tumors opens the feasibility of being used as biomarker distinguishing the tumor aggressiveness and prognostic indicators for human prostate cancer |
709810 |
| 3.4.21.B42 | medicine |
negative kallikrein 11 expression is associated with nearly 5fold increased risk of distant metastasis after curative gastrectomy in gastric cancer patients. Kallikrein 11 expression is a significant independent prognostic factor for disease-free survival and overall survival in gastric cancer patients |
718041 |
| 3.4.21.B42 | diagnostics |
the measurement of kallikrein-related peptidase 11, KLK11, might be a useful diagnostic and prognostic test for non-small cell lung cancer patients. Patients with a high enzyme activity have a longer longer overall survival and progression free survival |
732964 |
| 3.4.21.B42 | diagnostics |
elevated tumor tissue protein expression levels of kallikrein-related peptidases KLK10 and KLK11 are associated with a favorable prognosis in advanced high-grade serous ovarian cancer patients |
752430 |
| 3.4.21.B42 | diagnostics |
KLK11 splice variants represent potential cancer biomarkers |
752890 |
